文献速递糖尿病

2型糖尿病中胰岛素与胰高血糖素样肽1受体激动剂联合治疗:随机对照试验的系统评价与Meta分析

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Diabetes Care · 2017-01-01

该系统评价与Meta分析纳入26项随机对照试验、共11425例成人2型糖尿病患者,比较基础胰岛素联合胰高血糖素样肽1受体激动剂(GLP-1RA)与其他注射类降糖治疗。联合治疗较其他注射治疗降低HbA1c(WMD=-0.47%,95%CI -0.59至-0.35)、增加达标患者比例(RR=1.65,95%CI 1.44-1.88)、体重降低(WMD=-2.5 kg,95%CI -3.3至-1.7),低血糖事件相似(RR=1.14,95%CI 0.93-1.39)。

要点

  • 基础胰岛素联合GLP-1RA较其他注射治疗降低HbA1c(WMD=-0.47%),达标比例更高(RR=1.65)。
  • 与基础-餐时胰岛素方案相比,联合治疗血糖控制相似,低血糖更少(RR=0.66)且体重降低(WMD=-4.7 kg)。
  • 固定比例复方制剂结果与总体分析相似(HbA1c WMD=-0.56%),但异质性高(I²>89%)且部分结局存在发表偏倚。

核心结论

  • GLP-1RA单用或与基础胰岛素组成可滴定固定比例复方制剂,可能成为口服药控制不佳的2型糖尿病患者推进基础胰岛素治疗或起始注射治疗的有前景选择。
  • 需要更长期的研究来评估其持久性和耐受性。

研究设计与样本

  • 系统评价与Meta分析,检索截至2016年11月的多个电子数据库,纳入26项随机对照试验,随访12-52周,共11425例成人2型糖尿病患者。
  • 采用随机效应模型计算加权均数差(WMD)或相对危险度(RR)及95%CI。

主要发现

  • 联合治疗与其他注射治疗总体比较:HbA1c降低(WMD=-0.47%,95%CI -0.59至-0.35),达标(HbA1c≤7%,53 mmol/mol)患者更多(RR=1.65,95%CI 1.44-1.88),低血糖事件相似(RR=1.14,95%CI 0.93-1.39),体重降低(WMD=-2.5 kg,95%CI -3.3至-1.7)。
  • 总体分析异质性高(I²>89%,P<0.001),三个结局存在显著发表偏倚。
  • 预设亚组分析中,联合治疗与基础-餐时胰岛素方案相比血糖控制相似,低血糖更少(RR=0.66,95%CI 0.46-0.93),体重降低(WMD=-4.7 kg,95%CI -6.9至-2.4)。
  • 固定比例复方制剂结果与总体分析相似(HbA1c WMD=-0.56%,95%CI -0.72至-0.40)。

关键数值与推荐

  • HbA1c达标定义为≤7%(53 mmol/mol)。
  • 联合治疗与其他注射治疗总体比较:HbA1c WMD=-0.47%(95%CI -0.59至-0.35);达标RR=1.65(95%CI 1.44-1.88);低血糖RR=1.14(95%CI 0.93-1.39);体重WMD=-2.5 kg(95%CI -3.3至-1.7)。
  • 与基础-餐时胰岛素方案比较:低血糖RR=0.66(95%CI 0.46-0.93);体重WMD=-4.7 kg(95%CI -6.9至-2.4)。
  • 固定比例复方制剂:HbA1c WMD=-0.56%(95%CI -0.72至-0.40)。

临床怎么用

  • 作者认为,GLP-1RA单用或与基础胰岛素组成可滴定固定比例复方制剂,可能成为口服药控制不佳的2型糖尿病患者推进基础胰岛素治疗或起始注射治疗的有前景选择。
  • 作者指出需要更长期的研究来评估其持久性和耐受性。

局限性

  • 总体分析异质性高(I²>89%,P<0.001)。
  • 三个结局存在显著发表偏倚。
  • 需要更长期的研究来评估持久性和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The combination of basal insulin plus a glucagon-like peptide 1 receptor agonist (GLP-1RA) has been proposed as a treatment option to intensify insulin therapy in type 2 diabetes. We performed a meta-analysis of randomized controlled trials (RCTs) comparing this combination strategy to other injectable antidiabetes treatments on metabolic control in adult patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted an electronic search until November 2016 on many electronic databases to identify RCTs assessing changes in HbA1c, proportion of patients at HbA1c target ≤7% (53 mmol/mol), hypoglycemia, and weight change. We used a random-effect model to calculate the weighted mean difference (WMD) or relative risk (RR) with the 95% CI. RESULTS: We identified 26 RCTs, lasting 12-52 weeks, and involving 11,425 patients. When the combination strategy was compared with other injectable treatments (overall data), there were reductions in HbA1c (WMD = -0.47%, 95% CI -0.59 to -0.35), more patients at HbA1c target (RR = 1.65, 95% CI 1.44-1.88), similar hypoglycemic events (RR = 1.14, 95% CI 0.93-1.39) and a reduction in weight (WMD = -2.5 kg, 95% CI -3.3 to -1.7), with high heterogeneity (I2 > 89%, P < 0.001) and a significant publication bias for three outcomes. In preplanned subgroup analyses, the combination treatment was similar to basal-bolus insulin regimens for glycemic control, with less hypoglycemia (RR = 0.66, 95% CI 0.46-0.93) and reduced weight (WMD = -4.7 kg, 95% CI -6.9 to -2.4). Fixed-ratio combinations yielded results similar to the overall analysis (HbA1c WMD = -0.56%, 95% CI -0.72 to -0.40). CONCLUSIONS: GLP-1RAs alone or as titratable fixed-ratio combinations with basal insulin may represent a promising option to advance basal insulin therapy or to initiate injectable therapy in patients with type 2 diabetes inadequately controlled on oral agents. Longer studies are needed to assess durability and tolerability.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017. PMID: 28325801. doi:10.2337/dc16-1957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。